Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 947 of 6351
-
Could extra white cells boost immune recovery in kids with tough leukemia?
Disease control OngoingAlthough most children with leukaemia are cured using drugs (chemotherapy) alone, for some children additional treatments are needed. Stem cell transplant can cure children where chemotherapy and other drugs have failed. In this case, the immune cells of the donor attack the leuk…
Sponsor: University of Manchester • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New Dual-Action drug shows promise in early lung cancer trial
Disease control OngoingThis is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and efficacious in participants with Advanced or Metastatic Non-small Cell Lung Cancer.
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New combo shows promise for Tough-to-Treat colorectal cancer
Disease control CompletedEncorafenib is currently being developed (with or without binimetinib), in combination with cetuximab, for the treatment of adult patients with B-RAF proto-oncogene, serine/threonine kinase V600E mutant (BRAF V600E) metastatic colorectal cancer (mCRC), who have received prior sys…
Phase 2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Jun 27, 2026 12:27 UTC
-
Targeted combo aims to replace chemo in HER2+ breast cancer
Disease control OngoingRandomized phase III trial of trastuzumab + Alpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with PIK3CA mutated previously treated HER2+ Advanced Breast cancer.
Phase 3 • Sponsor: Spanish Breast Cancer Research Group • Aim: Disease control
Last updated Jun 26, 2026 15:03 UTC
-
New hope for kids with rare cancers: alectinib trial launches
Disease control OngoingThis study will evaluate the safety, pharmacokinetics, and efficacy of alectinib in children and adolescents with ALK fusion-positive solid or CNS tumors for whom prior treatment has proven to be ineffective or for whom there is no satisfactory standard treatment available.
Phase 1/2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug aims to wipe out cancer protein in Tough-to-Treat blood cancers
Disease control Recruiting nowStudy consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)
Phase 1/2 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New hope for myositis: early IVIg may boost recovery
Disease control OngoingIn patients with myositis early immunomodulation by intensive treatment ("hit-early/hit-hard" principle) may induce faster reduction of disease activity and prevent chronic disability. Intravenous immunoglobulin (IVIg) in addition to standard treatment with glucocorticoids may be…
Phase 2/3 • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New drug shows promise for lupus in asian patients
Disease control CompletedThe purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in Asian participants with active systemic lupus erythematosus (SLE).
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New radiation beads take on standard chemo for liver cancer
Disease control CompletedTo evaluate the efficacy and safety of TheraSphereTM yttrium \[90Y\] glass microsphere in the Chinese patients with inoperable hepatocellular carcinoma.
Phase 3 • Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New pill targets tough cancers: early trial shows promise
Disease control CompletedPhase Ia: To evaluate the safety/tolerability of GFH925 in subjects with KRAS G12C-mutated advanced solid tumors; To estimate the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of GFH925. Phase Ib: To evaluate the efficacy of GFH925 in subjects with KRAS G…
Phase 1/2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
CBD gel shows promise for fragile x behaviors in major trial
Symptom relief CompletedThis is a randomized, double-blind, placebo-controlled, multiple-center study, to assess the efficacy and safety of cannabidiol administered as ZYN002 for the treatment of children, adolescent, and young adult patients with Fragile X syndrome (FXS). Eligible participants will par…
Phase 3 • Sponsor: Harmony Biosciences Management, Inc. • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control CompletedThis trial is an open-label, single-arm clinical study. The main purpose is to verify the safety and efficacy of CAR-T cell preparations in the treatment of CEA-positive advanced malignant tumors, and to obtain the recommended dose and infusion scheme of CAR-T cell preparations f…
Phase 1 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New procedure may stop debilitating arm swelling after breast cancer surgery
Prevention Recruiting nowLymphedema is a chronic, progressive, and debilitating condition that occurs with disruption or obstruction of the lymphatic system, which commonly occurs a result of breast cancer therapy. The purpose of this study is to determine if the use of a low risk lymphatic reconstructio…
Sponsor: Stanford University • Aim: Prevention
Last updated Aug 14, 2026 00:00 UTC
-
Can a chatbot help african american kidney donors decide with confidence?
Knowledge-focused CompletedLiving donor (LD) kidney transplantation is the optimal treatment for patients with end-stage kidney disease (ESKD). However, LDs take on a higher risk of future ESKD themselves. African American (AA) LDs have an even greater, 3.3-fold, risk of ESKD than white LDs post-donation. …
Sponsor: Northwestern University • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
New hope for kids with painful mouth sores: drug trial launches
Disease control Recruiting nowThe aim of this study is to estimate the efficacy of apremilast compared to placebo in the treatment of oral ulcers in pediatric participants from 2 to \< 18 years of age with oral ulcers associated with Behçet's disease (BD) through week 12.
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New combo therapy shows promise for Tough-to-Treat kidney cancer
Disease control CompletedThis study will be comparing tivozanib in combination with nivolumab to tivozanib alone in subjects with advanced Renal Cell Carcinoma (RCC) who have had 1 or 2 prior lines of therapy, one of which was an Immune Checkpoint Inhibitor (ICI).
Phase 3 • Sponsor: AVEO Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New oral drug could offer hope for Tough-to-Treat eczema
Disease control CompletedThis was a parallel treatment, Phase 2, double-blind, 2-arm, placebo-controlled study with 2 staggered cohorts (2 arms in each cohort) to evaluate the efficacy and safety of rilzabrutinib in adult participants (aged at least 18 years) with moderate-to-severe AD and intolerance or…
Phase 2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug duo offers hope for Hard-to-Treat lymphoma
Disease control OngoingThis research study is evaluating the combination of two drugs, copanlisib and venetoclax, as a possible treatment for trelapsed/refractory diffuse large B-cell lymphoma (DLBCL) The names of the study drugs involved in this study are: * Copanlisib * Venetoclax
Phase 1/2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Can a prostate cancer scan also spot liver tumors?
Diagnosis CompletedThe purpose of the research is to evaluate the use of a PSMA PET/CT (Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography) scan in the diagnosis of HCC (hepatocellular carcinoma) and comparing it to standard scanning techniques with CT (Computed…
Phase 2 • Sponsor: Peter MacCallum Cancer Centre, Australia • Aim: Diagnosis
Last updated Aug 20, 2026 00:00 UTC
-
Tailored therapy could boost outcomes in elderly myeloma patients
Disease control Recruiting nowFrailty is dynamic and confers poor outcomes in elderly patients with newly diagnosed multiple myeloma (NDMM), mainly because of the high prevalence of treatment discontinuation due to intolerability. We designed a multi-center prospective study (DynaFiT) based on our real-life p…
Sponsor: FengYan Jin • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC